# A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure

> **NCT00504608** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 150 (actual)

## Conditions studied

- Infertility Implantation Failure

## Interventions

- **DRUG:** Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)

## Key facts

- **NCT ID:** NCT00504608
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2004-04
- **Final completion:** 2004-04
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2017-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00504608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00504608, "A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00504608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*